INOVIQ’s EXO-OC Test Data Under Embargo, Patent Filing Imminent

Context of Recent Share Price Movements

INOVIQ Limited (ASX: IIQ), a biotechnology company focused on early detection of ovarian cancer, has responded to an ASX price query following a notable increase in its share price and trading volume in late May 2025. The company confirmed that it is not aware of any undisclosed information that could explain the recent market activity beyond what has already been publicly released.

Clarifying the ASCO Abstract and Prior Disclosures

INOVIQ highlighted that an abstract detailing the performance of its EXO-OC test was published online by the American Society of Clinical Oncology (ASCO) on May 22, 2025. This abstract reiterates the results previously announced in December 2024 and referenced in subsequent quarterly and half-year reports, investor presentations, and webinars. The company emphasized that this abstract does not contain new or materially price-sensitive information beyond what the market already knows.

Upcoming ASCO Poster Presentation and Patent Protection

Crucially, INOVIQ pointed to a forthcoming poster presentation at the ASCO Annual Meeting in Chicago on June 1, 2025, which will reveal new data considered price sensitive. This presentation remains under strict embargo until its public release on the day of the event. Early disclosure is prohibited by ASCO’s embargo policy, which protects the company’s reputation and its relationships with collaborators and industry partners.

Simultaneously, the University of Queensland is preparing an Australian Provisional Patent Application (APPA) based on the new data contained in the poster. This patent filing, expected by May 30, 2025, is critical to safeguarding intellectual property rights related to the EXO-OC test. INOVIQ is relying on ASX Listing Rule 3.1A to withhold early disclosure of the poster data, citing confidentiality and the ongoing patent application process.

Implications for Investors and Market Compliance

INOVIQ confirmed full compliance with ASX continuous disclosure obligations and emphasized that its board has authorised the responses to the ASX query. The company’s careful navigation of disclosure rules reflects the sensitive nature of the upcoming data release and the strategic importance of patent protection in the competitive biotech landscape.

For investors, the awaited ASCO presentation and patent filing represent significant milestones that could influence the company’s valuation and market perception. The EXO-OC test’s promising performance in early ovarian cancer detection, as previously reported, positions INOVIQ at the forefront of diagnostic innovation.